Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_95
Snippet: Heatmaps comparing variance in drug potency measured by in vivo EC50 (x-axis) and timing of treatment initiation (y-axis) for A. Shedding duration, B. viral load area under the curve (AUC) and C. extent of T cell response required for viral elimination. Potent therapy within the first 5 days of infection limits shedding duration and the extent of the T cell response. However, only extremely early therapy during the pre-symptomatic phase of infect.....
Document: Heatmaps comparing variance in drug potency measured by in vivo EC50 (x-axis) and timing of treatment initiation (y-axis) for A. Shedding duration, B. viral load area under the curve (AUC) and C. extent of T cell response required for viral elimination. Potent therapy within the first 5 days of infection limits shedding duration and the extent of the T cell response. However, only extremely early therapy during the pre-symptomatic phase of infection lowers viral AUC. Sub-potent therapy given during the extremely early pre-symptomatic stage may extend shedding duration at lower viral loads by limiting the effector cell response.
Search related documents:
Co phrase search for related documents- AUC curve and drug potency: 1
- AUC curve and infection limit: 1, 2, 3
- AUC curve and potent therapy: 1
- AUC curve and pre symptomatic phase: 1, 2
- AUC curve and Shedding duration: 1, 2, 3, 4, 5, 6
- AUC curve viral load area and cell response: 1, 2
- AUC curve viral load area and drug potency: 1
- AUC curve viral load area and pre symptomatic phase: 1, 2
- AUC curve viral load area and Shedding duration: 1, 2, 3
- cell response and drug potency: 1
- cell response and effector cell response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cell response and infection limit: 1, 2, 3, 4
- cell response and potent therapy: 1
- cell response and pre symptomatic phase: 1, 2
- cell response and Shedding duration: 1, 2, 3
- drug potency and potent therapy: 1, 2
- drug potency and pre symptomatic phase: 1
- drug potency and Shedding duration: 1, 2
- duration shed and Shedding duration: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date